BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2154857)

  • 1. Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study.
    Einhorn LH; Pennington K; McClean J
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):32-5. PubMed ID: 2154857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: a Hoosier Oncology Group Trial.
    Faylona EA; Loehrer PJ; Ansari R; Sandler AB; Gonin R; Einhorn LH
    J Clin Oncol; 1995 May; 13(5):1209-14. PubMed ID: 7738623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
    Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
    J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study.
    Wolff AC; Ettinger DS; Neuberg D; Comis RL; Ruckdeschel JC; Bonomi PD; Johnson DH
    J Clin Oncol; 1995 Jul; 13(7):1615-22. PubMed ID: 7602350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K; Fukuoka M; Nishiwaki Y; Kurita Y; Watanabe K; Noda K; Ariyoshi Y; Tamura T; Saijo N
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hoosier Oncology Group studies in extensive and recurrent small cell lung cancer.
    Einhorn LH; Loehrer PJ
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):28-31. PubMed ID: 7846539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer.
    Saxman S; Loehrer PJ; Logie K; Stephens D; Workman F; Scullin D; Einhorn LH; Ansari R
    Invest New Drugs; 1991 Aug; 9(3):253-6. PubMed ID: 1664423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily oral etoposide in the treatment of cancer.
    Einhorn LH
    Semin Oncol; 1991 Feb; 18(1 Suppl 2):43-7. PubMed ID: 1846980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pilot phase II study of hybrid chemotherapy of CAV-PVP in small cell lung cancer (SCLC)].
    Ueoka H; Ohnoshi T; Hiraki S; Kawahara S; Numata T; Nishii K; Yonei T; Yamashita H; Moritaka T; Kiura K
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2251-5. PubMed ID: 2544149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL; Rudd R; Ruiz de Elvira MC; James L; Gower N; Harper PG; Tobias JS; Partridge MR; Davison AG; Trask C
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer.
    Einhorn LH; Crawford J; Birch R; Omura G; Johnson DH; Greco FA
    J Clin Oncol; 1988 Mar; 6(3):451-6. PubMed ID: 2832549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party.
    Girling DJ
    Lancet; 1996 Aug; 348(9027):563-6. PubMed ID: 8774567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
    J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined alkylators and multiple-site irradiation for extensive small cell lung cancer: a Southwest Oncology Group Study.
    Livingston RB; Schulman S; Mira JG; Harker G; Vogel S; Coltman CA; Rivkin SE; Budd GT; Grever MR; Crowley JP
    Cancer Treat Rep; 1986 Dec; 70(12):1395-401. PubMed ID: 3024826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.